ca88

2024Äê11ÔÂ11-14ÈÕ£¬È«Çò¹æÄ£×î´ó¡¢Ó°ÏìÁ¦×î¹ãµÄÒ½ÁÆÆ÷еչ»áÖ®Ò»MEDICA£¬Ôڵ¹ú¶ÅÈû¶û¶à·òÊ¢·Å×ÝÐС£×÷ΪÖ×ÁöÔçɸºÍÒºÌå»î¼ìÁìÓòµÄÁì¾üÆóÒµ£¬ca88ÉúÎSinglera Genomics£©Ð¯¶àÏîÁ¢Òì²úÆ·ºÍÊÖÒÕ¾ªÑÞÁÁÏ࣬ÓëÀ´×ÔÌìϸ÷µØµÄÏàÖúͬ°éÉîÈë̽ÌÖÖ×ÁöÔçɸÔçÕïÁìÓòµÄÇ°ÑØÏ£ÍûÓëÏàÖú»úÔµ¡£

ÔÚÕ¹»áÉÏ£¬±¸ÊܹØ×¢µÄÃ÷ÐDzúÆ·ÊÇColonAiQ^®£¨ÑªÒº³¦°©¶à»ùÒò¼×»ù»¯Ó«¹âPCRÊÔ¼ÁºÐ£©¡£Õâ¿î²úÆ·²»µ«Äܹ»ÊµÏÖ½áÖ±³¦°©µÄÔçÕ»¹¿ÉÓÃÓÚ³¦°©¸ùÖÎÊõºó¸´·¢µÄÕ¹ÍûÓë¼à²â¡£Ïà±È¹Å°åµÄÓ°Ïñѧ¡¢ÂÑ°××éѧ£¬ColonAiQ^®Ê¹ÓÃÑ­»·Ö×ÁöDNA£¨ctDNA£©¾ßÓÐʵʱ¡¢ÎÞ´´¡¢±ã½ÝµÈÓÅÊÆ¡£»¹¿ÉÓÃ×÷I-IIIÆÚ½áÖ±³¦°©Êõºó¸´·¢Î£º¦Éý¸ßµÄ·Ö×Ó±ê¼ÇÎï^[1]¡£

±ðµÄ£¬ÎÒÃÇ»¹´øÀ´ÁËÕë¶Ô¸Îϸ°û°©µÄ¸¨ÖúÕï¶ÏºÍ»¼ÕßÔ¤ºóÆÀ¹ÀµÄ¼×»ù»¯Ð²úÆ·——HepaAiQ^®¡£¸Ã²úÆ·ÔÚHCC£¨Hepatocellular Carcinoma£©µÄ¸¨ÖúÕï¶ÏÖÐÌåÏÖ¾«²Ê£¬ÆäÌØÒìÐÔºÍѸËٶȾùÏÔÖø¸ßÓڹŰåµÄAFPºÍDCPÖ¸±ê£¬ÓÐÖúÓÚ¸üÔçµØ·¢Ã÷HCC»¼ÕߵIJ¡Ç飬²¢ÎªÔ¤·ÀÐÔɸ²éºÍÁÆЧ¼à¿ØÌṩ¸ü±ã½ÝµÄ¼à²â¹¤¾ß^[2]¡£

³ýÁ˲úÆ·³öº£Ä£Ê½£¬ca88ÉúÎﻹÓëÀ´×ÔÅ·Ö޺ͱ±ÃÀ¡¢À­ÃÀµÄDZÔÚÏàÖúͬ°éÉîÈë̽ÌÖÁËÁ¢ÒìÊÖÒÕ³öº£µÄÏàÖúģʽ£¬²¢¸æ¿¢Æձ鹲ʶ¡£ÎÒÃǺÜÊÇ×ÔºÀµØÏÈÈÝÁËÕë¶ÔÒÈÏÙ°©£¨PDAC£©µÄÔçÆÚɸ²éÊÖÒÕ——PDACatch™£¬¿É»ùÓÚ¶þ´ú²âÐòƽ̨ÉÏ×ÊÖú¸ßΣº¦ÒÈÏÙ°©»¼Õ߸üÔçµØ·¢Ã÷Σº¦²¢ÊµÊ±¸ÉÔ¤¡£Õâ¿î²úÆ·ÔøÈÙ»ñÃÀ¹úFDAµÄÍ»ÆÆÐÔÆ÷еÈ϶¨£¨Breakthrough Devices Designation£©¡£

ca88ÉúÎïÔÚMEDICAÕ¹»áÉϵľ«²ÊÌåÏÖ£¬ÕÃÏÔÁËÆóҵǿʢµÄÆ·ÅÆÕкôÁ¦ÒÔ¼°ÁÉÀ«µÄ¹ú¼ÊÊг¡Éú³¤Ô¶¾°¡£³ýÁËÓëÏàÖúͬ°éClinomics EuropeÅäºÏÍƳöColonAiQ^®¼ì²âЧÀÍÍ⣬ҲÔÚ2024 MEDICAÊÕ»ñÁËÀ´×ÔÅ·ÖÞ¡¢À­ÃÀ¡¢Öж«¡¢¶«ÄÏÑǵȶàµØ¾­ÏúÉ̵ÄÏàÖúÒâÔ¸¡£

лл¸÷È˶Ôca88ÉúÎïµÄ¹Ø×¢ÓëÖ§³Ö£¬ÎÒÃǽ«¼ÌÐøÆð¾¢£¬ÓëÌìϸ÷µØµÄÏàÖúÆóÒµ¡¢ÙÉÐÐÃÇÅäºÏÍƶ¯È«ÈËÀàµÄÖ×ÁöÕï¶Ï·ÀÖÎÊÂÒµ£¬ÎªÈ«ÇòµÄÖ×Áö»¼ÕßÌṩ¸ü׼ȷ¡¢±ã½Ý¡¢¸ßÐԼ۱ȵÄÕï¶Ï½â¾ö¼Æ»®£¡In China, for the world!

²Î¿¼ÎÄÏ×£º

[1] Mo S. Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation[J]. JAMA Oncol. 2023 Jun 1;9(6):770-778.

[2] Guo, D.-Z., et al., Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study. Clinical and Translational Medicine, 2024. 14(5): p. e1652.